200133-16-0

Basic information

• Product Name: Propanoic acid, 3,3'-[[2-[(2-carboxyethoxy)methyl]-2-[[(phenylmethoxy)carbonyl]amino]-1 ,3-propanediyl]bis(oxy)]bis-
• CAS NO: 200133-16-0
• Molecular Formula: C21H29NO11
• Molecular Weight: 471.461
• Mol File: 200133-16-0.mol
• Article Data: 25

Chemical Properties

• CAS DataBase Reference: Propanoic acid, 3,3'-[[2-[(2-carboxyethoxy)methyl]-2-[[(phenylmethoxy)carbonyl]amino]-1 ,3-propanediyl]bis(oxy)]bis-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 3,3'-[[2-[(2-carboxyethoxy)methyl]-2-[[(phenylmethoxy)carbonyl]amino]-1 ,3-propanediyl]bis(oxy)]bis-(200133-16-0)
• EPA Substance Registry System: Propanoic acid, 3,3'-[[2-[(2-carboxyethoxy)methyl]-2-[[(phenylmethoxy)carbonyl]amino]-1 ,3-propanediyl]bis(oxy)]bis-(200133-16-0)

Safety Data

• Hazardous Substances Data: 200133-16-0(Hazardous Substances Data)

Upstream product

• 200133-15-9 N-(Benzyloxycarbonyl)-tris[((methoxycarbonyl)ethoxy)methyl]aminomethane 
• 200133-20-6 di-tert-butyl 3,3'-((2-(((benzyloxy)carbonyl)amino)-2-((3-(tert-butoxy)-3-oxopropoxy)methyl)propane-1,3-diyl)bis(oxy))dipropionate 
• 501-53-1 benzyl chloroformate 
• 175724-30-8 tris{[2-(tert-butoxycarbonyl)ethoxy]methyl}methylamine 
• 166047-75-2 tris[(carboxyethoxy)ethyl](amino)methane trimethyl ester 
• 132491-89-5 tris(cyanoethoxymethyl)aminomethane 
• 132491-90-8 3-[2-Amino-3-(2-ethoxycarbonyl-ethoxy)-2-(2-ethoxycarbonyl-ethoxymethyl)-propoxy]-propionic acid ethyl ester 
• 220431-66-3 benzyl N-{tris[2-(ethoxycarbonyl)ethoxymethyl]methyl}carbamate 

Downstream Products

• 200133-17-1 benzyl N-tris[2-{[({tris[[2-(methoxycarbonyl)ethoxy]methyl]methyl}amino)carbonyl]ethoxy}methyl]methylcarbamate 
• 200133-20-6 di-tert-butyl 3,3'-((2-(((benzyloxy)carbonyl)amino)-2-((3-(tert-butoxy)-3-oxopropoxy)methyl)propane-1,3-diyl)bis(oxy))dipropionate 
• 404887-91-8 benzyl N-tris[(2-{[(tris{[2-(tert-butoxycarbonyl)ethoxy]methyl}methyl)amino]carbonyl}ethoxy)methyl]methylcarbamate 
• 220431-66-3 benzyl N-{tris[2-(ethoxycarbonyl)ethoxymethyl]methyl}carbamate 
• 490040-40-9 C₆₃H₉₈N₁₀O₂₀ 
• 132491-90-8 3-[2-Amino-3-(2-ethoxycarbonyl-ethoxy)-2-(2-ethoxycarbonyl-ethoxymethyl)-propoxy]-propionic acid ethyl ester 

Relevant articles and documents

Assessing changes in the expression levels of cell surface proteins with a turn-on fluorescent molecular probe

Tri-nitrilotriacetic acid (NTA)-based fluorescent probes were developed and used to image His-tagged-labelled outer membrane protein C (His-OmpC) in liveEscherichia coli. One of these probes was designed to light up upon binding, which provided the means

Receptor-Specific Delivery of Peptide Nucleic Acids Conjugated to Three Sequentially Linked N-Acetyl Galactosamine Moieties into Hepatocytes

Peptide nucleic acids (PNAs) are DNA analogs that bind with high affinity to DNA and RNA in a sequence-specific manner but have poor cell permeability, limiting use as therapeutic agents. The work described here is motivated by recent reports of efficient gene silencing specifically in hepatocytes by small interfering RNAs conjugated to triantennary N-acetyl galactosamine (GalNAc), the ligand recognized by the asialoglycoprotein receptor (ASGPR). PNAs conjugated to either triantennary GalNAc at the N-terminus (the branched architecture) or monomeric GalNAc moieties anchored at Cγ of three consecutive PNA monomers of N-(2-aminoethyl)glycine (aeg) scaffolds (the sequential architecture) were synthesized on the solid phase. These formed duplexes with complementary DNA and RNA as shown by UV and circular dichroism spectroscopy. The fluorescently labeled analogs of GalNAc-conjugated PNAs were internalized by HepG2 cells that express the ASGPR but were not taken up by HEK-293 cells that lack this receptor. The sequential conjugate was internalized about 13-fold more efficiently than the branched conjugate into HepG2 cells, as demonstrated by confocal microscopy. The results presented here highlight the potential significance of the architecture of GalNAc conjugation for efficient uptake by target liver cells and indicate that GalNAc-conjugated PNAs have possible therapeutic applications.

MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP

The invention features a mononucleotide comprising a nucleobase bonded to a sugar having a 3'-carbon and a 5'-carbon, where the 5'-carbon is bonded to a phosphorus (V) atom of a phosphate group through an oxygen atom, the phosphorus (V) atom being bonded to (i) a disulfide bioreversible group through an oxygen atom; and (ii) (a) optionally substituted amino, optionally substituted alkoxy, optionally substituted aryloxy, or optionally substituted heteroaryloxy; or (b) the 3'-carbon through an oxygen atom. The invention also features methods of delivering the mononucleotide to a cell and methods of treating a subject having Hepatitis C.